Promedica International

What Promedica International does

Promedica International is a US-based contract research organization (CRO) specializing exclusively in ophthalmology clinical trials for pharmaceutical, biotechnology, and medical device sponsors. Founded in 1984 and headquartered in Costa Mesa, California, the company operates with a headcount of 11–50 employees across East Coast and West Coast offices, delivering end-to-end trial execution from protocol development through regulatory submission. Its service architecture covers anterior and posterior segment indications, including novel retinal therapies (gene and cell therapy), complex ocular device trials, and programs from early-phase through pivotal stages, supported by an established global investigator network for North American and international delivery.

The firm's go-to-market is a high-touch enterprise sales motion targeting drug and device sponsors, delivered through direct engagement, inside-sales phone contacts, and a B2B content presence via its website and LinkedIn. Its value proposition rests on 100% ophthalmology exclusivity, a regulatory track record of supporting 10 of the 23 FDA-approved ophthalmic drugs since 2008, and a single-vendor lifecycle model that compresses handoffs between design, operations, and regulatory affairs. Revenue mechanics are professional-services engagements scoped by protocol, duration, and complexity; pricing is not publicly disclosed.

In January 2024, Promedica International was acquired by iuvo Bioscience (now operating as iuvo Clinical), forming an end-to-end ophthalmology research platform that spans preclinical development through clinical submission. The combined entity retains Promedica's brand and clinical specialty under a broader strategic acquirer that now provides capital, complementary capabilities, and cross-sell pathways into earlier-stage sponsors—an important context for any evaluation of its standalone trajectory or integration risk.

Name

Promedica International

Legal name

Promedica International

Website

https://promedica-intl.com

Company type

Private

Founded year

1984

Operating status

Acquired

Headcount range

11–50 employees

Short description

Promedica International is a US-based, ophthalmology-exclusive contract research organization (CRO) that runs end-to-end clinical trials for pharma, biotech, and ocular-device sponsors, having supported 10 of the 23 FDA-approved ophthalmic drugs since 2008. It was acquired by iuvo Bioscience (now iuvo Clinical) in January 2024.

Ownership category

akta.pro rank

Product category

Ophthalmology Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Ophthalmology clinical trials
• Contract research organization
• Clinical trial management
• Ophthalmic drug development
• Retinal therapy research

Headquarters

HQ city

Costa Mesa

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Contract research organization providing ophthalmology-focused clinical trial management services including protocol development, clinical operations, regulatory affairs, and submission support. Revenue is generated through service contracts with pharmaceutical and biotech sponsors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Promedica International (now operating under iuvo Clinical post-acquisition) is an ophthalmology-focused contract research organization (CRO) providing end-to-end clinical trial services to pharmaceutical and biotech sponsors. Services span protocol development, clinical operations, regulatory affairs, and submission support for ophthalmic therapies including novel retinal therapies and complex ocular device trials across anterior and posterior segments.

Product overview

Promedica International was a specialized ophthalmology contract research organization that was acquired by Iuvo Bioscience in January 2024. Following the acquisition, the combined entity created an end-to-end ophthalmology research platform spanning preclinical through clinical development stages, with capabilities across anterior and posterior eye segments for retinal therapies and ocular device trials.

Differentiator

Problem solved

Functional benefit

Products and services

• End-to-End Clinical Trial Management for Ophthalmology Comprehensive clinical trial management services spanning the full lifecycle of ophthalmic drug and device development for pharmaceutical and biotech sponsors. Includes protocol design, clinical operations, site management, regulatory affairs, and submission support across anterior and posterior segment indications.
• Ophthalmic Drug Clinical Trials (Retinal and Anterior/Posterior Segment) Specialized clinical trial services for novel ophthalmic drug development including retinal therapies, gene therapies, cell therapies, and novel drug delivery systems. Supports early-phase through pivotal trials for sponsors pursuing FDA approval of ophthalmic therapeutics.
• Ocular Medical Device Clinical Trials Clinical trial design and execution services for ocular medical devices requiring regulatory approval, supporting device trial design complexity and global trial execution for medical device companies.
• Regulatory Affairs and Submission Support Regulatory affairs services supporting FDA submission for ophthalmic drugs and devices, including regulatory strategy, submission preparation, and FDA interaction support.
• Global Clinical Trial Network Management Management of clinical trials across a global network of sites spanning North America and international locations, while preserving the responsiveness and attention to detail of a focused ophthalmology-only CRO.

Quantifiable outcome

• Supported 10 of 23 FDA-approved ophthalmic drugs since 2008

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• iuvo BiosciencecoreStrategic or Co-development Partner · 1 January 2024In January 2024, US-based iuvo Bioscience acquired Promedica International to create an end-to-end ophthalmology research platform spanning preclinical through clinical development stages. This acquisition combined Promedica International's expertise with iuvo's existing capabilities to form a comprehensive ophthalmology CRO offering.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• IQVIA: World's largest CRO with a dedicated ophthalmology therapeutic center of excellence. Comparable as the broadest incumbent able to bundle ophthalmology with data, RWE, and central lab services.
• Charles River Laboratories: Preclinical and early-stage CRO with growing clinical services footprint. Comparable given iuvo's preclinical heritage and potential adjacency as the combined platform expands its end-to-end offering.
• Syneos Health: Top global CRO with biotech-focused commercial and clinical offerings including ophthalmology. Comparable as a broad incumbent pursuing the same sponsor relationships at scale.
• ICON plc: Global top-5 CRO offering full-service clinical development including ophthalmology studies. Comparable as a broad incumbent with dedicated therapeutic units competing for ophthalmology sponsors.
• Medpace: Large full-service CRO with strong biotech sponsor base and growing ophthalmology book. Comparable as a larger incumbent expanding into the same specialty clinical trial space.
• Worldwide Clinical Trials: Mid-to-large global CRO with therapeutic-area specialization including ophthalmology. Comparable as a broader-scope specialty CRO competitor.

Direct peers

• Premier Research: Mid-size CRO with a dedicated ophthalmology therapeutic area and pediatric/specialty focus. Directly comparable on ophthalmology clinical services and similar sponsor-segment focus.
• Clinipace Worldwide: Mid-size full-service CRO serving biotech and specialty pharma. Comparable as a similarly sized, therapeutic-area-oriented CRO bidding on the same niche sponsor contracts.
• Rho: Mid-size full-service CRO with therapeutic-area depth across multiple specialties. Comparable as a similarly-sized CRO competitor pursuing complex, regulated studies for small-to-mid biotech sponsors.
• Ora, Inc. Specialty ophthalmology CRO offering end-to-end clinical research services to pharma and biotech sponsors. Directly comparable as another boutique, ophthalmology-only CRO competing for the same sponsor programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/promedica-international

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Promedica International